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Abstract 
 
Aims. To evaluate transferability of cardiovascular outcome trials (CVOTs) on GLP-1 receptor agonists (GLP-
1RA) to the real-world population of type 2 diabetic (T2D) patients. We assessed which proportion of real-
world patients constitute CVOT-like populations. 
Materials and methods. We applied inclusion/exclusion (I/E) criteria of each GLP-1RA CVOT on a cross-
sectional database of 281,380 T2D patients from Italian diabetes outpatient clinics. We calculated the 
proportion of patients eligible for each CVOT and compared their clinical characteristics with those of trial 
patients. In addition, we used a Bayesian network-based method to sample the greatest subsets of real-world 
patients yielding true CVOT-like populations. 
Results. Between 98,725 and 124,164 T2D patients could be evaluated for CVOT eligibility. After excluding 
patients who already where on GLP-1RA and applying I/E criteria, 35.8% of patients would be eligible for 
REWIND, 34.1% for PIONEER-6, 13.4% for EXSCEL, 10.1% for SUSTAIN-6, 9.5% for HARMONY and 
9.4% for LEADER. 45.4% of patients could be eligible for at least one of the CVOTs. These patients, however, 
were extremely different from trial patients for most clinical characteristics. The greatest CVOT-like subset of 
real-world patients was 0.5% for SUSTAIN-6, 1.0% for EXSCEL, 1.2% for LEADER, 1.8% for PIONEER-
6, and 7.9% for REWIND. 
Conclusions. A very small proportion of real-world patients constitute true CVOT-like populations. These 
findings question whether any meaningful information can be drawn from applying trial I/E criteria to real-
world T2D patients. Transferability of CVOT findings to clinical practice should rather rely on observational 
effectiveness studies. 
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Introduction 
 
Randomized controlled trials (RCTs) provide the highest level of evidence to guide therapeutic decisions. By 
means of randomization, blinding, and appropriate controls, RCTs establish causal relationships between 
treatments and effects. In the field of diabetes pharmacotherapy, cardiovascular outcome trials (CVOTs) are a 
form of RCTs primarily designed to address cardiovascular safety of new glucose lowering medications 
(GLMs). To satisfy regulatory requirements on drug safety, CVOTs evaluate specific GLM against placebo 
(1). Although designed primarily to demonstrate non-inferiority, some recent CVOTs have shown that active 
treatment was superior to placebo in reducing the rates of major adverse cardiovascular outcome events 
(MACE) and other adverse outcomes in patients with type 2 diabetes (T2D). In addition, in post-hoc analyses, 
some molecules also showed capacity to reduce the rate of adverse renal endpoints. Results of these CVOTs 
have been incorporated into consensus algorithms for the treatment of T2D, which now prioritize certain GLM 
for the prevention of cardio-renal complications (2).  
This is the case for glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose contransporter-
2 inhibitors (SGLT-2i). Dedicated CVOTs showed superiority of liraglutide (LEADER), semaglutide 
(SUSTAIN-6), albiglutide (HARMONY), and dulaglutide (REWIND) versus placebo in reducing the rates of 
the classical 3-point MACE (cardiovascular death, non-fatal myocardial infarction or stroke) (3-6). The CVOT 
(EXSCEL) on exenatide once weekly (exeOW) showed nearly significant reductions in MACE and nominally 
significant reduction in mortality rates (7), while oral semaglutide (PIONEER-6) nominally reduced total and 
cardiovascular risk (8). Therefore, there is general agreement that GLP-1RA as a class are able to prevent or 
delay adverse cardiovascular outcomes in T2D (9). 
However, transferability of CVOT findings to clinical practice may not be immediate because of the many 
differences between the trial setting and routine care. Specifically, CVOTs recruited patients based on rigorous 
inclusion / exclusion (I/E) criteria and closely followed them at regular intervals within strict trial experimental 
protocols. Since the CVOT framework is mostly event-driven, I/E criteria have been designed to allow 
collection of the desired number of events in a relatively short time. To this end, T2D patients at baseline high 
cardiovascular risk had to be enrolled, such as those with a prior history of cardiovascular disease and/or 
multiple risk factors. Since only about 30% of T2D patients in routine care show signs of macroangiopathy, to 
what extent results of CVOTs can be translated to T2D patients at lower cardiovascular risk is a matter of 
debate. While the vast majority of patients in LEADER, SUSTAIN-6, and HARMONY had established 
cardiovascular disease (4-6), almost 70% of patients in the REWIND study had no prior history of 
cardiovascular events, revascularization, or cardiac ischemia (3). Although there are some differences among 
the various GLP-1RA, positive results of the REWIND study suggest that this class of GLM can prevent 
cardiovascular events irrespectively of the baseline cardiovascular risk (9; 10). 
A few studies have recently evaluated what proportion of T2D patients from various clinical care settings 
would satisfy I/E criteria to be enrolled in specific CVOTs. Expectedly, such proportion was inversely related 
to the pre-specified trial baseline cardiovascular risk (11-14). However, applying CVOT I/E criteria to real-
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world T2D populations may yield patients subgroups that are substantially different from the actual CVOT 
populations, thereby leaving the question of transferability unanswered. 
In this study, we applied I/E criteria for GLP-1RA CVOTs to a specialist care population of T2D patients from 
the DARWIN-T2D (DAta for Real World evIdeNce in Type 2 Diabetes) study of the Italian Diabetes Society. 
In addition to providing proportion of patients satisfying I/E criteria for each CVOTs, we show how much the 
eligible population of patients actually differs from those of CVOTs and calculate what proportion of patients 
from routine care would generate a true CVOT-like population. 
 
 
Methods 
 
Data source. The DARWIN-T2D study was conducted by the Italian Diabetes Society and was initially 
designed to evaluate dapagliflozin in the real world. Protocol details and primary analysis have been published 
before (15; 16). The DARWIN-T2D database contains cross-sectional information on about 281k T2D patients 
from 46 diabetes outpatient clinics from all over Italy. Data were collected at each center at the last available 
visit in 2015-2016. All clinics used the same electronic chart system to store patients’ data (MyStar Connect / 
Smart Digital Clinic, Meteda Srl, San Benedetto del Tronto, Italy). Relevant data were extracted by a dedicated 
software without manual intervention.  
We recorded the following information: demographics (age, sex, diabetes duration), anthropometrics (height, 
weight, BMI, waist circumference), cardiovascular risk factors (smoke, blood pressure values, lipid profile), 
estimated glomerular filtration rate (CKD-EPI equation) and other laboratory data (including urinary albumin 
excretion rate and liver enzymes), and medications for the treatment of diabetes and other cardiovascular risk 
factors or conditions. In addition, detailed information were collected on diabetic complications from ICD-9 
codes in the electronic chart, including: presence and stage of retinopathy and diabetic macular oedema; 
presence or absence of somatic or autonomic diabetic neuropathy; history of stroke, transient ischemic attack, 
or carotid endoarterectomy / stenting; history of angina, myocardial infarction, or coronary revascularization; 
presence / absence of left ventricular hypertrophy and history of heart failure; history of claudication, limb 
ischemia or amputation; presence of asymptomatic atherosclerosis of coronary, carotid, or leg arteries. 
Not all records were complete for all patients: degree and distribution of missing variables has been shown 
before (15). 
 
Data analysis. We retrieved, from the respective publications, I/E criteria of the following CVOTs on GLP-
1RA: LEADER (liraglutide) (6), SUSTAIN-6 (semaglutide) (5), EXSCEL (exeOW) (7), REWIND 
(dulaglutide) (3), PIONEER-6 (oral semaglutide) (8), HARMONY (albglutide) (4). Specific I/E criteria had to 
be adapted to the available data in the DARWIN-T2D database with some modifications (Table S1). For 
instance, the following information used for CVOT I/E criteria were not available: myocardial ischemia stress 
test or imaging; diastolic dysfunction; ankle-brachial index; calcitonin levels, history of cancer and 
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pancreatitis. Timing of prior cardiovascular events and revascularization was not available to exclude patients 
with recent events. Since no information on contraception was available, women of childbearing potential were 
excluded. Patients with missing information for key I/E variables were excluded from the analysis. 
We thus identified T2D patients who would be eligible into each of the considered CVOTs and calculated the 
respective proportion over the total background population of patients with available data. Then, we compared 
the average clinical characteristics of eligible patients with average clinical characteristics of patients in the 
database who were already on GLP-1RA and with those of patients actually enrolled in CVOTs (from the 
respective publications). 
Finally, we extracted from the DARWIN-T2D database the largest subgroup of patients who had average 
clinical characteristics superimposable to those of CVOTs. Since, no specific tool is available for this case 
sampling procedure, we devised an analytical strategy as described below. 
 
Statistical analysis. For descriptive purposes, continuous variables are expressed as mean and standard 
deviation, whereas categorical variables are expressed as percentage. To evaluate to what extent two groups 
of patients were similar, we computed the absolute standardized mean difference (SMD) for each variable. 
Conventionally, a SMD value of 0.1 or less is considered indicative of a good balance. For example, for 
continuous variables, a SMD <0.1 means that the difference between means of the two groups is <10% of the 
pooled standard deviation. Due to the very large sample size in each comparison, p-values were not calculated, 
as several minor and clinically-irrelevant differences would yield p-values<0.05.   
 
Sampling RCT-like populations. Continuous variables in the database were categorized into five classes, on 
the basis of each RCT summary statistics and assuming a normal distribution. Observations with at least one 
missing value were removed. A Bayesian network (BN) was constructed on the case complete dataset to obtain 
the conditional probability distributions, which reflect the dependencies among variables. Then, conditional 
probability distributions were used to get the joint distribution of variables from which a final probability of 
inclusion in the RCT of each patients in the database was computed (17). The PC (Peter-Clark) stable algorithm 
with a 100-fold bootstrap was employed for the structural learning of the BN (i.e. for identifying the 
relationships among variables). A more robust BN was obtained by averaging the 100 BNs learned, considering 
only the relationships among variables present in at least 95% of times (18) Finally, we assigned to each 
variable category appropriate weights to reflect the same proportion of patients included in the RCT. Patients 
of the DARWIN-T2D database to be included in the RCT were randomly sampled according to the final 
probability computed on basis of the BN joint distribution. Balancing between the patients sampled and the 
RCT’s patients was evaluated through SMD. To get SMD smaller than 0.1 we proceeded in the following way: 
first, we balanced the two groups according to a SMD smaller than 0.2 for each variable. To obtain this result, 
for each variable with SMD greater than 0.2, patients with values in the tails of the distribution were removed. 
The group of patients selected in this way was removed by the DARWIN-T2D dataset and the procedure was 
repeated to get a new random sample of patients balanced according to SMD smaller than 0.2. Finally, all the 
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balanced groups obtained were joint together, and again to obtain for each variable SMD smaller than 0.1 the 
same procedure was applied. A sensitivity analysis on different thresholds of SMD was carried out, and the 
choice of the double threshold 0.2 and 0.1 turned out to get the greatest balanced group. All the analyses were 
performed using R version 3.5.0. 
 
 
Results 
 
The original dataset was composed of 281,380 patients. Since the minimum requirement to enter the database 
was T2D diagnosis, many patients had missing values for several of the variables needed to evaluate CVOT 
I/E criteria. Among 130,380 patients with available information on GLM, 6699 (5.1%) were being treated with 
a GLP-1RA (73.8% liraglutide; 23.5% exeOW; 2.7% lixisenatide). The number of patients who could be 
evaluated for CVOT eligibility was 124,164 for EXSCEL, 116,553 for PIONEER-6, 107,040 for HARMONY, 
106,606 for LEADER, 105,074 for REWIND, and 98,725 for SUSTAIN-6.  
After excluding patients who already where on GLP-1RA and applying I/E criteria as outlined Table S1, we 
calculated that the percentage of patients who would be eligible for CVOTs was 35.8% for REWIND, 34.1% 
for PIONEER-6, 13.4% for EXSCEL, 10.1% for SUSTAIN-6, 9.5% for HARMONY and 9.4% for LEADER. 
45.4% of patients could be eligible for at least one of the CVOTs considered.  
Clinical characteristics of patients treated with GLP-1RA and of those who could be eligible for CVOTs are 
illustrated in Table 1. 
We observed that the average clinical characteristics of patients who could be eligible for CVOTs were 
substantially different from the average clinical characteristics of patients who composed each CVOT 
population (Figure 1A). For instance, patients selected from the real-world database were older than in CVOTs. 
In addition, despite 80-100% of patients in the LEADER and SUSTAIN-6 had established cardiovascular 
disease, application of I/E criteria to the real-world population yielded patients with a 70-80% prevalence of 
microangiopathy (mostly chronic kidney disease) and a lower prevalence of macroangiopathy (40-50%). Most 
other clinical characteristics were imbalanced between patients enrolled in CVOTs and real-world patients 
eligible for the same CVOTs (Table 2). Out of 11 key clinical variables, eligible patients matched trial 
characteristics for just 2 or 3 variables, with the notable exception of REWIND. Real-world patients eligible 
for REWIND were matched with the REWIND population for 6/11 variables. 
We then evaluated which proportion of real-world patients would constitute a population of individuals with 
key average characteristics similar to those enrolled in CVOTs. The largest dataset of real-world patients 
yielding CVOT-like populations was 0.5% for SUSTAIN-6, 1.0% for EXSCEL, 1.2% for LEADER, 1.8% for 
PIONEER-6, and 7.9% for REWIND. We were unable to obtain a meaningful dataset of real-word patients 
who would match the population of the HARMONY study (Figure 1B). 
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Discussion 
 
Although 10-35% of real-world T2D patients could be enrolled in GLP-1RA CVOTs, their clinical 
characteristics were substantially dissimilar from those of CVOT populations and from those of typical patients 
who are treated with GLP-1RA. The proportion of real-world patients who have true average CVOT-like 
characteristics is much smaller, ranging from 0.5% to 7.9%. 
CVOTs have shown notable capacity of some GLP-1RA to reduce the rate of adverse cardiovascular outcomes 
in patients with T2D (9), but transferability of such findings from the trial setting to clinical practice is 
challenging. CVOTs are designed to assess non-inferiority or superiority compared to placebo in the best 
possible experimental conditions. To this end, CVOTs enrol highly selected patients, whose characteristics are 
intended to maximize the probability of trial success. Consequently, some CVOT populations have very high 
prevalence of established cardiovascular disease, while representativeness of the real-world population of T2D 
is rarely an issue considered in CVOT design. Thus, to what extent clinical benefits observed in GLP-1RA 
CVOTs can be transferred to T2D patients in everyday clinical practice remains unclear.  
Prior studies have examined what proportion of patients from clinical practice databases would be eligible for 
CVOTs on GLP-1RA or SGLT-2i. By analysing an U.S. adult T2D database, Boye et al. reported proportions 
of patients eligible for the LEADER, SUSTAIN-6, EXSCEL, and REWIND that were quite similar to those 
shown in our study (13). Small different were likely due to geographical differences, e.g. being Italian T2D 
patients less obese than North American ones. The high proportion of patients eligible for PIONEER-6 (8) in 
our study reflects enrolment criteria that, differently from those of EXSCEL (7), lacked constrains on the ratio 
between patients with established cardiovascular disease or multiple cardiovascular risk factors. 
Similar analyses have been performed on CVOTs for SGLT-2i (12; 14). Nicolucci et al. used an Italian 
database of diabetes outpatient clinics similar to ours and showed that real-world T2D patients eligible for 
CVOTs on SGLT-2i were different from trial populations in many instances (11).  
By analysing GLP-1RA CVOTs, we found substantial differences between the eligible real-world populations 
and trial populations. For instance, the resulting PIONEER-6 eligible subsets, although relatively large, was 
greatly imbalanced compared to the true PIONEER-6 population (8). We thus examined which proportion of 
patients from the real-world database would generate CVOT-like populations. To this end, we used a Bayesian 
method to sample patients from a large dataset based on given average clinical characteristics. We found that 
the greatest subset of patients with CVOT-like characteristics was much smaller than the proportion of eligible 
patients. Interestingly, we found no subset of real-world patients matching the HARMONY trial population, 
possibly because all HARMONY patients had established cardiovascular disease at a relatively young age (4). 
This important finding highlights that CVOT populations are extremely specific and that they are poorly 
represented by real-world T2D patients. Notably, however, REWIND confirmed as the CVOT mostly 
represented within the T2D population, although only 7.9% of real-world patients are truly REWIND-like. On 
the contrary, the apparently large generalizability of PIONEER-6 based on I/E criteria was not confirmed. 
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Our results question whether any conclusion can be drawn from applying trial I/E criteria to real-world T2D 
patients. In fact, the resulting subsets of T2D patients were more aged, with HbA1c closer to target, and with 
a prevalence of chronic kidney disease often exceeding that of cardiovascular diseases. That the benefits 
observed in CVOTs automatically apply to these real-world populations seems questionable. That all these 
patients should receive a GLP-1RA only because they were potentially eligible in successful CVOTs is also 
hardly arguable.  
We acknowledge that, in view of the potentially wide cardiovascular benefits of GLP-1RA, this class of GLM 
is far underutilized among T2D patients (19). However, transferability of trial findings to clinical practice 
should not be based on trial I/E criteria, but on the results of observational studies evaluating real-world 
effectiveness of GLP-1RA. Several real-world studies on glycaemic and extra-glycaemic effectiveness of 
GLP-1RA have confirmed findings from phase III RCTs (20-22). While many observational studies on SGLT-
2i have largely confirmed CVOT results in lower-risk populations (23-25), there is still a striking scarcity of 
cardiovascular effectiveness studies on GLP-1RA (26). In a small study from The Health Improvement 
Network database (UK), intensification of oral therapy by adding GLP-1RA was associated with lower 
cardiovascular events rate than intensification with insulin (27). We advocate that future larger cardiovascular 
effectiveness studies on GLP-1RA will shed light on transferability of CVOT findings to clinical practice. 
 
 
Acknowledgements 
We wish to thank Alessia Russo, secretariat of the Italian Diabetes Society, for the invaluable technical support. 
 
Funding 
The DARWIN-T2D database was established by the Italian Diabetes Society with an initial support from 
AstraZeneca. The present analysis has been supported by an unrestricted educational grant from Novo Nordisk. 
The external sponsors had no role in study design, data analysis and interpretation, and decision to publish. 
 
Conflict of interest disclosure 
GPF received grant support, lecture or advisory board fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, 
Mundipharma, NovoNordisk, Sanofi, Genzyme, Servier, Abbott, Novartis, Merck Sharp & Dohme.  
EO… 
OL… 
FQ… 
SM… 
AC has received consultancy or speaker fees from Abbott, AstraZeneca, Boehringer-Ingelheim, Bruno  
Farmaceutici, Janssen, Eli-Lilly, Merck Sharp & Dohme, Novartis, NovoNordisk, Roche, Sanofi-Aventis, 
Servier, Takeda. He Also Received Research Grants From Eli-Lilly and NovoNordisk.  
9 
 
AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, 
Novartis, Boeringher-Ingelheim, Sanofi, Mediolanum, Janssen, NovoNordisk. PLV, MP, GF have nothing to 
disclose. 
VS and PB have nothing to disclose. 
 
Author contribution 
Study design: VS, PB, AC, AA, GPF. Data collection and analysis: VS, PB, EO, OL, SM, FQ, GPF. 
Manuscript writing: VS, PB, AC, AA, GPF. Manuscript revision: EO, OL, SM, FQ. All authors approved the 
final version of the manuscript. 
 
Composition of the DARWIN-T2D database 
Agostino Consoli and Gloria Formoso (Dipartimento di Medicina e Scienze dell’Invecchiamento - Università 
Degli studi G. D’Annunzio di Chieti-Pescara); Giovanni Grossi (Ospedale San Francesco di Paola - Azienda 
Sanitaria Provinciale di Cosenza); Achiropita Pucci (Azienda Sanitaria Provinciale di Cosenza); Giorgio Sesti 
and Francesco Andreozzi (Azienda Ospedaliero Universitaria di Catanzaro); Giuseppe Capobianco (Azienda 
Sanitaria Locale Napoli 2 Nord); Adriano Gatti (Ospedale San Gennaro dei Poveri - Azienda Sanitaria Locale 
Napoli 1 Centro); Riccardo Bonadonna, Ivana Zavaroni and Alessandra Dei Cas (Azienda Ospedaliero 
Universitaria di Parma); Giuseppe Felace (Ospedale di Spilimbergo - Azienda per l’Assistenza Sanitaria n.5 
Friuli Occidentale); Patrizia Li Volsi (Ospedale di Pordenone - Azienda per l’Assistenza Sanitaria n.5 Friuli 
Occidentale); Raffaella Buzzetti and Gaetano Leto (Ospedale Santa Maria Goretti - Azienda Sanitaria Locale 
di Latina); Gian Pio Sorice (Fondazione Policlinico Universitario A. Gemelli, Roma); Paola D’Angelo 
(Ospedale Sandro Pertini - Azienda Sanitaria Locale Roma 2); Susanna Morano (Azienda Ospedaliera 
Universitaria Policlinico Umberto I, Roma); Antonio Carlo Bossi (Ospedale di Treviglio - Azienda Socio 
Sanitaria Territoriale Bergamo Ovest); Edoardo Duratorre (Ospedale Luini Confalonieri di Luino - Azienda 
Socio Sanitaria Territoriale Sette Laghi); Ivano Franzetti (Ospedale Sant’Antonio Abate di Gallarate - Azienda 
Socio Sanitaria Territoriale Valle Olona); Paola Silvia Morpurgo (Ospedale Fatebenefratelli - Azienda Socio 
Sanitaria Territoriale Fatebenefratelli Sacco); Emanuela Orsi (Fondazione IRCCS Ca’ Granda - Ospedale 
Maggiore Policlinico di Milano); Fabrizio Querci (Ospedale Pesenti Fenaroli di Alzano Lombardo - Azienda 
Socio Sanitaria Territoriale Bergamo Est); Massimo Boemi† and Federica D’Angelo (Presidio Ospedaliero di 
Ricerca INRCA-IRCCS di Ancona); Massimiliano Petrelli (Azienda Ospedaliero Universitaria Ospedali 
Riuniti di Ancona); Gianluca Aimaretti and Ioannis Karamouzis (Azienda Ospedaliero Universitaria Maggiore 
della Carità di Novara); Franco Cavalot (Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano); 
Giuseppe Saglietti† (Ospedale Madonna del Popolo di Omegna - Azienda Sanitaria Locale Verbano Cusio 
Ossola); Giuliana Cazzetta (Casa della Salute, Ugento - Distretto Socio Sanitario Gagliano del Capo - Azienda 
Sanitaria Locale di Lecce); Silvestre Cervone (Presidio ospedaliero San Marco in Lamis - Distretto Socio 
Sanitario San Marco in Lamis - Azienda Sanitaria Locale di Foggia); Eleonora Devangelio (Distretto Socio 
Sanitario di Massafra - Azienda Sanitaria Locale di Taranto); Olga Lamacchia (Azienda Ospedaliero 
10 
 
Universitaria Ospedali Riuniti di Foggia); Salvatore Arena (Ospedale Umberto I – Azienda Sanitaria 
Provinciale di Siracusa); Antonino Di Benedetto (Azienda Ospedaliera Universitaria Policlinico G. Martino di 
Messina); Lucia Frittitta (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di 
Catania); Carla Giordano (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Salvatore Piro 
(Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Manfredi Rizzo, 
Roberta Chianetta and Carlo Mannina (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Roberto 
Anichini (Ospedale San Jacopo di Pistoia – Azienda USL Toscana Centro); Giuseppe Penno (Azienda 
Ospedaliero Universitaria Pisana); Anna Solini (Azienda Ospedaliera Universitaria Pisana); Bruno Fattor 
(Comprensorio Sanitario di Bolzano - Azienda Sanitaria della Provincia Autonoma di Bolzano); Enzo Bonora 
and Massimo Cigolini (Azienda Ospedaliero Universitaria Integrata di Verona); Annunziata Lapolla and Nino 
Cristiano Chilelli (Complesso Socio Sanitario Ai Colli - Azienda ULSS n.6 Euganea); Maurizio Poli (Ospedale 
Girolamo Fracastoro di San Bonifacio - Azienda ULSS n.9 Scaligera); Natalino Simioni and Vera Frison 
(Ospedale di Cittadella - Azienda ULSS n.6 Euganea); Carmela Vinci (Azienda ULSS n.4 Veneto Orientale). 
 
 
  
11 
 
References 
 
1. Kieffer CM, Robertson AS: Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes 
Clinical Study Initiation From 2008 to 2017. Ther Innov Regul Sci 2019:2168479019860122 
2. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler 
DJ, Buse JB: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American 
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 
2018;61:2461-2498 
3. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, 
Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, 
Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, 
Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu 
WH, Temelkova-Kurktschiev T: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a 
double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130 
4. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Sr., Granger CB, Jones NP, Leiter LA, 
Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S: Albiglutide and 
cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a 
double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-1529 
5. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, 
Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T: Semaglutide and Cardiovascular Outcomes 
in Patients with Type 2 Diabetes. N Engl J Med 2016;375:1834-1844 
6. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, 
Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB: Liraglutide and 
Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-322 
7. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson 
SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, 
Hernandez AF: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl 
J Med 2017;377:1228-1239 
8. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay 
I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsboll T, Warren ML, Bain SC: Oral Semaglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2019;381:841-851 
9. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV: 
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: 
a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 
2019;7:776-785 
12 
 
10. Mannucci E, Dicembrini I, Nreu B, Monami M: Glucagon-like peptide-1 receptor agonists and 
cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis 
and subgroup analysis of randomized controlled trials. Diabetes Obes Metab 2019; 
11. Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V: 
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for 
Clinical Practice. Adv Ther 2019;36:2895-2909 
12. Birkeland KI, Bodegard J, Norhammar A, Kuiper JG, Georgiado E, Beekman-Hendriks WL, Thuresson 
M, Pignot M, Herings RMC, Kooy A: How representative of a general type 2 diabetes population are patients 
included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. 
Diabetes Obes Metab 2018; 
13. Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, 
Lakshmanan MC: Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials 
to the overall type 2 diabetes population in the United States. Diabetes Obes Metab 2019;21:1299-1304 
14. Wittbrodt E, Chamberlain D, Arnold SV, Tang F, Kosiborod M: Eligibility of patients with type 2 diabetes 
for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the 
Diabetes Collaborative Registry. Diabetes Obes Metab 2019;21:1985-1989 
15. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A: Rationale and design of the DARWIN-T2D 
(DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian 
study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis 2017;27:1089-1097 
16. Fadini GP, Zatti G, Baldi I, Bottigliengo D, Consoli A, Giaccari A, Sesti G, Avogaro A: Use and 
effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes 
Obes Metab 2018;20:1781-1786 
17. Lauritzen SL: Graphical Models. Oxford Statistical Science Series 1996;Clarendon Press, Oxford. 
18. Scutari M: Bayesian Network Constraint-Based Structure Learning Algorithms: Parallel and Optimized 
Implementations in the bnlearn R Package. Journal of statistical software 2017;77 
19. Fadini GP, Frison V, Rigato M, Morieri ML, Simioni N, Tadiotto F, D'Ambrosio M, Paccagnella A, 
Lapolla A, Avogaro A: Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of 
type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetol 2019; 
20. Morieri ML, Rigato M, Frison V, Simioni N, D'Ambrosio M, Tadiotto F, Paccagnella A, Lapolla A, 
Avogaro A, Fadini GP: Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in 
type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab 
2019;21:2542-2552 
21. Fadini GP, Sciannameo V, Franzetti I, Bottigliengo D, D'Angelo P, Vinci C, Berchialla P, Arena S, Buzzetti 
R, Avogaro A: Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined 
endpoints in routine clinical practice: A multicentre retrospective study. Diabetes Obes Metab 2019;21:1886-
1894 
13 
 
22. Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M, Lando LF: Adherence, persistence, glycaemic 
control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or 
exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab 
2018; 
23. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Deruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette 
LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S: Empagliflozin and the Risk of Heart Failure 
Hospitalization in Routine Clinical Care. Circulation 2019;139:2822-2830 
24. Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, 
Jorgensen ME, Wittbrodt ET, Thuresson M, Bodegard J, Hammar N, Fenici P: Rates of myocardial infarction 
and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-
world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab 2018;20:1983-1987 
25. Udell JA, Yuan Z, Rush T, Sicignano NM, Galitz M, Rosenthal N: Cardiovascular Outcomes and Risks 
After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based 
Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the 
Real World). Circulation 2018;137:1450-1459 
26. Chatterjee S, Davies MJ, Khunti K: What have we learnt from "real world" data, observational studies and 
meta-analyses. Diabetes Obes Metab 2018;20 Suppl 1:47-58 
27. Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I: Cardiovascular events and all-cause mortality with 
insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart 2016;102:1581-1587 
 
14 
 
Table 1. Clinical characteristics of patients treated with GLP-1RA and of those eligible for CVOTs. 
 
  GLP-1RA LEADER SUSTAIN-6 EXSCEL REWIND PIONEER-6 HARMONY 
Number 6699 10061 9942 16544 37574 39726 10208 
Percentage 5.1 9.4 10.1 13.4 35.8 34.1 9.5 
Age, years 61.7±9.5 74.2±8.4 74.2±8.5 70.8±8.6 70.8±7.1 73.7±8.3 73.6±9.1 
Sex male, % 54.9 56.5 55.8 67.3 59.0 57.6 68.4 
Diabetes duration, years 11.3±7.5 13.6±9.1 13.6±9.1 15.4±9.8 10.7±8.2 14.3±10.0 17.9±10.2 
Active smoke, % 19.8 13.5 13.6 17.1 14.3 14.0 16.1 
Body mass index, kg/m
2
 34.8±6.2 29.1±5.1 29.2±5.2 29.1±4.9 29.8±4.7 29.3±5.2 29.1±4.9 
Waist circumference, cm 114.7±13.6 103.9±12.2 104.1±12.4 104.2±11.9 104.5±11.3 104.5±12.6 104.6±11.9 
Systolic blood pressure, mm Hg 138.3±18.3 139.1±18.6 139.2±18.7 137.5±18.4 138.4±17.9 138.1±18.7 137.5±18.6 
Diastolic blood pressure, mm Hg 80.3±9.9 76.9±9.3 77.0±9.4 76.5±9.2 77.8±9.1 76.3±9.5 75.8±9.2 
Heart rate, bpm 78.8±11.9 73.3±11.9 73.5±11.8 71.7±11.6 73.3±11.8 72.8±11.8 70.2±11.0 
Fasting plasma glucose, mg/dl 151.2±42.7 151.3±36.9 155.6±42.1 150.2±42.2 136.8±33.7 146.4±47.7 160.4±50.5 
HbA1c, % 7.5±1.1 7.8±0.6 8.0±1.0 7.6±0.8 6.9±0.9 7.4±1.3 8.1±1.0 
Total cholesterol, mg/dl 169.3±37.5 168.2±38.2 169.0±38.8 160.5±38.3 170.0±37.4 166.8±38.8 158.2±39.6 
HDL cholesterol, mg/dl 45.9±12.6 48.7±13.6 48.4±13.5 47.1±13.6 49.8±13.8 49.0±14.5 45.7±13.4 
Triglycerides, mg/dl 160.2±87.5 141.5±74.2 144.2±76.5 140.9±85.3 134.6±71.7 137.4±77.6 146.9±88.5 
LDL cholesterol, mg/dl 91.9±32.3 91.4±32.2 91.9±32.7 85.3±31.7 93.3±32.1 90.5±32.6 83.1±32.2 
eGFR, ml/min/1.73 m
2
 87.7±24.1 68.3±21.5 68.5±21.9 73.3±21.6 76.2±19.4 66.7±20.5 68.9±22.1 
Albumin excretion rate, mg/g 51.5±147.7 59.5±98.7 61.2±109.5 42.5±108.7 45.3±66.0 57.1±155.0 43.4±132.1 
Glucose lowering medications, %        
Insulin 24.9 25.7 27.8 41.0 14.6 43.3 56.4 
Metformin 85.9 75.2 73.8 67.8 83.4 62.1 59.5 
Sulphonylurea / repaglinide 26.4 52.9 52.0 28.7 32.1 28.0 30.9 
Acarbose 2.0 3.5 2.7 1.8 2.2 2.6 2.4 
Pioglitazione 9.0 5.8 3.5 3.7 4.0 3.7 3.1 
DPP-4 inhibitors 0.2 0.0 0.0 27.6 0.0 0.0 28.0 
GLP-1RA 100.0 0.0 0.0 0.0 0.0 0.0 0.0 
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SGLT-2 inhibitors 0.7 5.7 5.4 4.5 3.4 3.6 5.4 
Other therapies, %        
Anti-platelet agents 46.4 58.5 58.5 74.6 51.3 60.9 84.0 
Statin 62.9 64.3 63.9 76.1 63.4 64.8 79.4 
Renin-angiotensin system blockers 74.5 71.2 71.3 74.0 70.7 72.1 75.9 
Calcium channel blockers 25.6 27.0 27.1 28.6 25.7 27.4 29.4 
Beta-blockers 31.5 36.4 36.6 44.5 32.7 36.9 49.7 
Diuretics 15.8 21.4 21.6 23.7 15.0 25.2 30.5 
Complications, %        
Chronic kidney disease 10.0 40.7 40.7 29.1 20.9 44.9 37.4 
Albuminuria >30 mg/g 37.3 59.0 59.7 33.5 40.7 57.6 32.1 
Retinopathy 15.6 16.1 16.6 24.9 11.4 17.9 31.2 
Peripheral neuropathy 14.8 21.2 21.8 25.9 17.2 23.5 30.4 
Atherosclerosis obliterans 12.4 27.2 27.7 48.3 13.8 26.1 60.9 
Peripheral revascularization 1.2 3.0 3.0 5.2 1.3 2.8 6.4 
Diabetic foot 7.6 13.0 13.6 15.9 10.0 12.4 19.3 
Stroke / Transient ischemic attack 2.2 9.5 9.8 11.3 4.8 9.3 14.4 
Carotid atherosclerosis 39.1 47.5 47.6 51.4 42.1 45.3 54.7 
Ischemic heart disease 8.2 20.9 20.9 44.2 11.7 21.0 56.7 
Coronary revascularization 6.0 13.5 13.5 29.9 7.5 13.6 37.9 
Microangiopathy 43.1 85.4 85.6 61.6 56.5 87.1 69.0 
Macroangiopathy 30.4 52.3 52.5 79.8 37.2 50.3 98.2 
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Table 2. Key clinical characteristics of real-world patients compared to CVOT patients. For each CVOT, 
we show the average clinical characteristics extracted from the respective publications, the characteristics of 
real-world patients who would be recruited into the CVOT based on inclusion / exclusion (I/E) criteria, and 
the characteristics of real-world patients sampled for being CVOT-like (Like). For both subgroups of real-
world patients, we calculated the standardized mean difference (SMD) as a measure of balance between 
groups. a SMD≤0.10 is conventionally considered indicative of a good balance. 
 
Variable LEADER I/E SMD Like SMD 
Number 9340 10061  1132  
Age, years 64.3 (7.2) 74.2 (8.4) 1.26 64.6 (7.6) 0.05 
Sex male, % 64.2 56.5 0.16 65.0 0.02 
Diabetes duration 12.8 (8.0) 13.6 (9.1) 0.09 13.5 (8.4) 0.09 
HbA1c, % 8.7 (1.5) 7.8 (0.6) 0.80 8.5 (0.8) 0.10 
BMI, kg/m2 32.5 (6.3) 29.1 (5.1) 0.60 32.7 (5.8) 0.03 
SBP, mm Hg 135.9 (17.7) 139.1 (18.6) 0.18 137.8 (18.7) 0.10 
DBP, mm Hg 77.1 (10.2) 76.9 (9.3) 0.02 78.2 (9.3) 0.10 
Heart failure, % 17.9 2.5 0.53 16.0 0.05 
Established CVD, % 81.4 55.7 0.58 81.4 0.001 
CVD risk factors, % 18.7 28.7 0.24 22.3 0.09 
eGFR, ml/min/1.73 m2 80.4 (21.0) 68.3 (21.5) 0.57 78.0 (26.5) 0.10 
Variable REWIND I/E SMD Like SMD 
Number 9901 37574  7280  
Age, years 66.2 (6.5) 70.8 (7.1) 0.66 66.7 (6.2) 0.08 
Sex male, % 53.9 59.0 0.10 59.3 0.10 
Diabetes duration 10.5 (7.2) 10.7 (8.2) 0.02 10.8 (7.1) 0.05 
HbA1c, % 7.3 (1.1) 6.9 (0.9) 0.42 7.4 (1.2) 0.06 
BMI, kg/m2 32.3 (5.7) 29.8 (4.7) 0.51 31.9 (5.3) 0.10 
SBP, mm Hg 137.0 (17.0) 138.4 (18.0) 0.08 137.2 (15.5) 0.01 
DBP, mm Hg 78.0 (9.9) 77.8 (9.1) 0.02 78.7 (8.1) 0.08 
Heart failure, % 8.7 1.0 0.36 7.3 0.05 
Established CVD, % 31.4 28.2 0.07 30.6 0.02 
CV risk factors, % 68.6 19.9 1.12 63.8 0.10 
eGFR, ml/min/1.73 m2 75.0 (22.1) 75.2 (21.2) 0.009 77.4 (22.2) 0.10 
Variable SUSTAIN-6 I/E SMD Like SMD 
Number 3297 9942  476  
Age, years 64.6 (7.4) 74.2 (8.5) 1.16 65.1 (6.7) 0.07 
Sex male, % 60.7 55.8 0.10 64.1 0.07 
Diabetes duration 13.9 (8.1) 13.6 (9.1) 0.00 14.5 (6.8) 0.07 
HbA1c, % 8.7 (1.5) 8.0 (1.0) 0.61 8.6 (0.7) 0.08 
BMI, kg/m2 32.8 (6.2) 29.2 (5.2) 0.66 32.8 (5.9) 0.004 
SBP, mm Hg 135.6 (17.2) 139.2 (18.7) 0.20 136.8 (17.5) 0.07 
DBP, mm Hg 77.0 (10.0) 77.0 (9.4) 0.00 77.8 (9.7) 0.08 
Heart failure, % 23.6 2.6 0.65 19.5 0.10 
Established CVD, % 83.0 55.7 0.62 80.5 0.07 
CV risk factors, % 17.0 29.0 0.29 14.1 0.08 
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eGFR, ml/min/1.73 m2 NA NA NA NA NA 
Variable PIONEER-6 I/E SMD Like SMD 
Number 3183 39726  1663  
Age, years 66.0 (7.0) 73.7 (8.3) 0.94 66.6 (7.2) 0.09 
Sex male, % 68.4 57.6 0.23 72.9 0.10 
Diabetes duration 14.9 (8.5) 14.3 (10.0) 0.06 14.0 (8.6) 0.10 
HbA1c, % 8.2 (1.6) 7.4 (1.3) 0.60 8.2 (0.7) 0.01 
BMI, kg/m2 32.3 (6.5) 29.3 (5.2) 0.57 32.0 (3.7) 0.05 
SBP, mm Hg 136.0 (18.0) 138.1 (18.7) 0.11 135.7 (14.0) 0.01 
DBP, mm Hg 74.0 (21.0) 76.3 (9.5) 0.21 77.0 (8.0) 0.10 
Heart failure, % 12.2 2.7 0.37 8.7 0.10 
Established CVD, % 84.7 58.1 0.62 80.7 0.10 
CV risk factors, % 15.3 27.8 0.31 19.1 0.10 
eGFR, ml/min/1.73 m2 76.0 (10.0) 66.2 (21.3) 0.47 71.6 (26.0) 0.10 
Variable EXSCEL I/E SMD Like SMD 
Number 14752 16544  915  
Age, years 62.0 (16.3) 70.8 (8.6) 0.69 62.3 (5.6) 0.02 
Sex male, % 62.0 67.3 0.11 62.4 0.008 
Diabetes duration 12.0 (7.4) 15.4 (9.8) 0.39 11.5 (6.9) 0.06 
HbA1c, % 8.0 (1.2) 7.6 (0.8) 0.40 7.9 (0.7) 0.10 
BMI, kg/m2 31.8 (5.9) 29.1 (4.9) 0.50 31.8 (5.9) 0.006 
SBP, mm Hg N/A N/A N/A N/A N/A 
DBP, mm Hg N/A N/A N/A N/A N/A 
Heart failure, % 16.2 2.9 0.46 12.6 0.10 
Established CVD, % 73.1 64.5 0.19 72.3 0.02 
CV risk factors, % 26.9 27.9 0.02 22.3 0.10 
eGFR, ml/min/1.73 m2 76.3 (22.9) 70.5 (25.5) 0.24 78.4 (31.5) 0.09 
Variable HARMONY I/E SMD Like SMD 
Number 9463 10208    
Age, years 64.1 (8.7) 73.6 (9.1) 1.07 N/A N/A 
Sex male, % 69.0 68.4 0.01 N/A N/A 
Diabetes duration 14.1 (8.7) 17.9 (10.3) 0.40 N/A N/A 
HbA1c, % 8.7 (1.5) 8.1 (1.0) 0.47 N/A N/A 
BMI, kg/m2 32.3 (5.9) 29.1 (4.9) 0.59 N/A N/A 
SBP, mm Hg 79.0 (25.5) 75.8 (9.2) 0.17 N/A N/A 
DBP, mm Hg 134.7 (16.5) 137.5 (18.6) 0.16 N/A N/A 
Heart failure, % 20.0 4.3 0.50 N/A N/A 
Established CVD, % 100.0 85.4 0.58 N/A N/A 
CV risk factors, % 0.0 33.6 1.00 N/A N/A 
eGFR, ml/min/1.73 m2 76.8 (10.1) 66.1 (25.6) 0.54 N/A N/A 
 
BMI, body mass index. SBP, systolic blood pressure. DBP, diastolic blood pressure. CVD, cardiovascular 
disease. eGFR, estimated glomerular filtration rate. N/A, not available. 
 
18 
 
Figure 1. Real-world patients and CVOTs. A) For each CVOT, the panels show standardized mean 
difference (SMD) between the actual trial population (retrieved from respective publications) and real-world 
patients selected based on inclusion/exclusion criteria (I/E) or for being CVOT-like (Like). In each plot, a 
dashed line indicates the SMD threshold of 0.1, indicating good balance. Fractions in brackets refer to the 
number of key clinical characteristics that are matched between real-world patients selected by I/E and trial 
characteristics. By design, all characteristics were balanced between CVOT-like patients and the respective 
CVOT population. B) Proportion of real-wold patients eligible for each CVOT based on I/E or sampled for 
being CVOT-like. 
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